Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O; Voriconazole/Bone Invasive Aspergillosis Study Group. Mouas H, et al. Among authors: herbrecht r. Clin Infect Dis. 2005 Apr 15;40(8):1141-7. doi: 10.1086/428734. Epub 2005 Mar 14. Clin Infect Dis. 2005. PMID: 15791514 Clinical Trial.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Herbrecht R, et al. N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191. N Engl J Med. 2002. PMID: 12167683 Free article. Clinical Trial.
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Patterson TF, et al. Among authors: herbrecht r. Clin Infect Dis. 2005 Nov 15;41(10):1448-52. doi: 10.1086/497126. Epub 2005 Oct 13. Clin Infect Dis. 2005. PMID: 16231256 Clinical Trial.
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers.
Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C, Wade A; Société Française de Greffe de Moelle et de Thérapie Cellulaire. Cordonnier C, et al. Among authors: herbrecht r. Clin Infect Dis. 2006 Apr 1;42(7):955-63. doi: 10.1086/500934. Epub 2006 Feb 22. Clin Infect Dis. 2006. PMID: 16511759
Clinical pharmacokinetics of voriconazole.
Levêque D, Nivoix Y, Jehl F, Herbrecht R. Levêque D, et al. Among authors: herbrecht r. Int J Antimicrob Agents. 2006 Apr;27(4):274-84. doi: 10.1016/j.ijantimicag.2006.01.003. Epub 2006 Mar 24. Int J Antimicrob Agents. 2006. PMID: 16563707 Review.
338 results